Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 16 04:00PM ET
21.34
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)- Insider Own34.64% Shs Outstand41.21M Perf Week12.32%
Market Cap840.37M Forward P/E- EPS next Y-5.30 Insider Trans0.00% Shs Float25.74M Perf Month9.44%
Income- PEG- EPS next Q-1.12 Inst Own72.17% Short Float14.00% Perf Quarter-6.49%
Sales- P/S- EPS this Y70.84% Inst Trans- Short Ratio11.57 Perf Half Y44.68%
Book/sh9.48 P/B2.25 EPS next Y-9.96% ROA- Short Interest3.60M Perf Year-
Cash/sh9.55 P/C2.24 EPS next 5Y- ROE- 52W Range13.14 - 33.92 Perf YTD-7.82%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-37.09% Beta-
Dividend TTM- Quick Ratio16.78 Sales past 5Y0.00% Gross Margin- 52W Low62.40% ATR (14)1.40
Dividend Ex-Date- Current Ratio16.78 EPS Y/Y TTM- Oper. Margin- RSI (14)56.42 Volatility5.90% 5.98%
Employees- Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price31.33
Option/ShortNo / Yes LT Debt/Eq0.07 EPS Q/Q-193.02% Payout- Rel Volume0.00 Prev Close21.34
Sales Surprise- EPS Surprise17.40% Sales Q/Q- EarningsMay 14 AMC Avg Volume311.42K Price21.34
SMA208.56% SMA50-4.73% SMA2001.53% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Dec-05-23Initiated Truist Buy $34
Dec-05-23Initiated TD Cowen Outperform
Dec-05-23Initiated JP Morgan Overweight $23
Dec-05-23Initiated Jefferies Buy $28
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Third Rock Ventures V, L.P.10% OwnerNov 14 '23Buy15.001,333,33319,999,9951,807,119Nov 14 07:08 PM
PERCEPTIVE ADVISORS LLCFormer 10% OwnerNov 14 '23Buy15.00666,6669,999,9902,912,835Nov 14 04:32 PM
Samsara BioCapital GP, LLC10% OwnerNov 14 '23Buy15.00666,6669,999,9904,121,689Nov 16 07:39 PM